Cargando…
The Worsening Renal Perfusion Index Predicts the Prognoses of Heart Failure Patients Treated with Sacubitril/Valsartan
INTRODUCTION: Sacubitril/valsartan (S/V) reduces all-cause mortality in patients with heart failure with reduced ejection fraction (HFrEF), but it may decline their estimated glomerular filtration rates (eGFR). In addition to eGFR, this clinical study aimed to develop a blood urea nitrogen (BUN)-bas...
Autores principales: | Hsu, Wan-Tseng, Cheng, Yu-Yang, Yang, Tsun-Yu, Chang, Chao-Kai, Lin, Yi-Hsuan, Lee, Chii-Ming, Huang, Tao-Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664343/ https://www.ncbi.nlm.nih.gov/pubmed/37708880 http://dx.doi.org/10.1159/000534095 |
Ejemplares similares
-
Anemia warrants treatment to improve survival in patients with heart failure receiving sacubitril–valsartan
por: Yang, Tsun-Yu, et al.
Publicado: (2022) -
Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022) -
Renal protective effect of sacubitril/valsartan in patients with heart failure
por: Hsieh, Hui-Ling, et al.
Publicado: (2021) -
Devastating Worsening Renal Function Following the Initiation of Sacubitril/Valsartan: Falling Between Two Stools
por: Sairaku, Akinori, et al.
Publicado: (2023) -
Sacubitril/valsartan in heart failure and end‐stage renal insufficiency
por: Heyse, Alex, et al.
Publicado: (2019)